Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Multicomponent Synthetic Conjugation: Redefining Chemical Bioconjugation for the Accelerated Production of Next-Generation Antibody-Drug Conjugates in Oncology

Project description

Streamlined discovery of drugs and linkers supports targeted immunotherapy

Antibody-drug conjugates (ADCs) – precision cancer treatments that use antibodies to deliver toxic drugs directly to tumour cells – have emerged as one of oncology’s most promising recent advances. Several ADCs have been commercialised but their production remains costly and slow, and guidelines are limited regarding increasing efficacy and safety. The ERC-funded MuSyC project aims to transform ADC development through ‘multicomponent synthetic conjugation’ which relies on multicomponent reactions to construct and attach functional components to antibodies in a single step. Supported by the development of DNA-based tools, it will speed the discovery of many more drug and linker combinations, enhance understanding of their key features and accelerate the development of improved next-generation ADCs.

Objective

Cancer remains one of the leading causes of death worldwide and in Europe in particular. In the continuous fight against this disease, the recent emergence of antibody-drug conjugates (ADCs) has unveiled tremendous hope for the patients. Composed of an antibody that binds cancer cells selectively, ADCs are capable of delivering a cytotoxic drug into tumors selectively, resulting in targeted cell death. Even though a dozen ADCs has already been marketed, they are still extremely expensive and time-consuming to produce. Besides, their development still lacks guiding principles to maximize their efficacy and increase their safety. At the moment, ADCs share the same structural canvas and are produced through the one- or two-step conjugation of antibodies, using a narrow set of linkers and drugs. These limitations represent a major barrier to innovation and to breakthroughs in this yet booming field, preventing the emergence of next-generation ADCs. My proposal to address these challenges is to focus on the bioconjugation step and use it as a chemical step toward the synthesis of valuable motifs. Using a novel chemical approach coined Multicomponent Synthetic Conjugation (MuSyC), I propose to use multicomponent reactions to construct and conjugate valuable motifs at the same time on antibodies, and expand the chemical space of bioconjugation. I will apply this strategy to selected cytotoxic drugs and peptide linkers, in order to streamline the development of the next generation of toxic immunoconjugates. In addition, I will also develop DNA-based tools to guide the discovery of site-selective conjugation reactions. This project will lead to next generations of toxic antibody conjugates, augment the current limited repertoire of approved drugs and linkers, while providing a better understanding of their key structural features.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 2 311 282,00
Address
RUE MICHEL ANGE 3
75794 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 2 311 282,00

Beneficiaries (1)